Continuing Education Information: Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care
© 2022 Harborside™
ARTICLE
Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care
This CE-certified supplement is jointly provided by
 |
 |
 |
|
Release date: June 30, 2022 |
Estimated time of completion: 2.5 hours |
|
Expiration date: July 1, 2023 |
Media: Certified journal article |
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg. Rancho Mirage, CA 92270
Phone: 760-773-4500
Fax: 760-773-4513
E-mail: contactce@annenberg.net
Journal of the Advanced Practitioner in Oncology
94 North Woodhull Road Huntington, NY 11743
Phone: 631-692-0800
Fax: 631-692-0805
E-mail: editor@advancedpractitioner.com
This certified activity is supported by educational grants from AbbVie, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; Legend Biotech; Oncopeptides, Inc.; Sanofi Genzyme; and Takeda Pharmaceuticals U.S.A., Inc.
Faculty
Kevin Brigle, PhD, ANP, VCU Massey Cancer Center, Richmond, Virginia
Donna Catamero, ANP-BC, OCN®, CCRC, Mount Sinai Health System, New York, New York
Kathleen Colson, RN, BSN, BS, Dana-Farber Cancer Institute, Boston Massachusetts
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Rebecca Lu, MS, FNP, The University of Texas MD Anderson Cancer Center, Houston, Texas
Kimberly Noonan, DNP, ANP-BC, AOCN®, Dana-Farber Cancer Institute, Boston, Massachusetts
Tiffany Richards, PhD, ANP-BC, AOCNP®, The University of Texas MD Anderson Cancer Center, Houston, Texas
Sandra Rome, RN, MN, AOCN®, CNS, Cedars-Sinai Medical Center, Los Angeles, California
Mary Steinbach, DNP, APRN, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Daniel Verina, DNP, ACNP-BC, Mount Sinai Medical Center, New York, New York
Intended Audience
The activity is designed for advanced practitioners (nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and pharmacists) who treat patients with multiple myeloma and plasma cell disorders.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Discuss symptoms and appropriate management associated with multiple myeloma treatment regimens for patients at different stages, from newly diagnosed through heavily pretreated.
- Develop awareness of health-care disparities and psychosocial impacts faced by patients with multiple myeloma.
- Employ strategies for improving patient adherence and satisfaction with treatment outcomes via approaches such as setting expectations and shared decision-making.
Continuing Education
Physician Assistants. This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 2.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 6/30/2022 to 7/1/2023. AAPA reference number: CMA-206342.
Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 2.5 contact hours, which includes 1.25 pharmacology hours, may be earned for successful completion of this activity.
Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-22-029-H01-P through #0797-9999-22-033-H01-P. This program is designated for up to 2.5 contact hours (0.25 CEUs) of continuing pharmacy education credit.
Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relationships with ACCME-defined ineligible companies.
The Annenberg Center for Health Sciences assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant financial relationships that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made.
Disclosures
Kevin Brigle, PhD, ANP, has served on speakers bureaus for AstraZeneca, Bristol Myers Squibb, Karyopharm, Oncopeptides, and Sanofi.
Donna Catamero, ANP-BC, OCN®, CCRC, has served on speakers bureaus for Oncopeptides and GSK and advisory boards for Bristol Myers Squibb, GSK, and Legend Biotech.
Kathleen Colson, RN, BSN, BS, has served as a consultant for Bristol Myers Squibb, Oncopeptides, and Sanofi.
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, has served as a consultant for Bristol Myers Squibb, GSK, Janssen, Karyopharm, Legend Biotech, Oncopeptides, Sanofi, and Takeda.
Rebecca Lu, MS, FNP, has nothing to disclose.
Kimberly Noonan, DNP, ANP-BC, AOCN®, has nothing to disclose.
Tiffany Richards, PhD, ANP-BC, AOCNP®, has served as a consultant for Bristol Myers Squibb, GSK, Janssen/Legend Biotech, Sanofi, and Takeda.
Sandra Rome, RN, MN, AOCN®, CNS, has nothing to disclose.
Mary Steinbach, DNP, APRN, has served on speakers bureaus for GSK and Karyopharm.
Daniel Verina, DNP, ACNP-BC, has served on speakers bureaus for Bristol Myers Squibb, GSK, Janssen, Karyopharm, Sanofi, and Takeda.
Additional Content Planners
Andrea Edwards, PA-C (Peer Reviewer), has served as a speaker for Pfizer.
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN (Nurse Planner), has served as a consultant for Bristol Myers Squibb, GSK, Janssen, Karyopharm, Legend Biotech, Oncopeptides, Sanofi, and Takeda.
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
Harborside and Harborside Medical Education staff have nothing to disclose.
International Myeloma Foundation staff have nothing to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
| Read the Certified Articles |
How to Earn Credit
Click the button below to access the learning assessment and evaluation form online.
| Earn Credit |
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.